Pramodini Medicare Share Price & Stock Analysis

Quick Answers

What is the Pramodini Medicare share price today? Pramodini Medicare is currently listed and trading. Check our charts for the latest listing performance.

Is Pramodini Medicare a good stock to buy? Review our AI forensic scores and fundamental analysis for Pramodini Medicare to understand the underlying financial health.

Key Stock Information

ViewIPO AI Analysis Score

The Pramodini Medicare Stock scored 78/100 (Moderate Risk) in our deep analysis.

Frequently Asked Questions

What business does Pramodini Medicare Limited operate?

Pramodini Medicare Limited is an Indian diagnostic service provider offering technology-enabled radiology, clinical laboratory, and nuclear medicine services across public and private hospitals, government PSUs, and medical colleges.

Where is Pramodini Medicare Limited headquartered?

Pramodini Medicare Limited is headquartered in Vijayawada, Andhra Pradesh, where it also operates its central processing laboratory and 24x7 teleradiology centre.

What is the total issue size of the Pramodini Medicare IPO?

The total issue size is ₹69.04 crore, consisting of a fresh issue of ₹63.14 crore (5,014,800 shares) and an Offer for Sale (OFS) of ₹5.90 crore (500,400 shares).

How will the proceeds from the fresh issue be utilized?

Net proceeds from the fresh issue will be utilized to fund capital expenditure of ₹45.15 crore for purchasing medical diagnostic equipment for existing and proposed centres, as well as for general corporate purposes.

What is the price band and lot size for the IPO?

The price band for Pramodini Medicare IPO is set at ₹110 to ₹118 per share with a minimum lot size of 1,200 shares (minimum investment of ₹2,64,000 at the lower band).

On which stock exchange will Pramodini Medicare Limited list?

The equity shares of Pramodini Medicare Limited are proposed to be listed on the NSE EMERGE SME platform.

Who is the book running lead manager and registrar for the IPO?

Smart Horizon Capital Advisors Private Limited is the Lead Manager (BRLM), and Purva Sharegistry India Private Limited is the Registrar for the IPO.

View IPO
View IPO
Home›India›Pramodini Medicare ()
Pramodini Medicare Logo

Pramodini MedicareNSE SME / BSE SME:

Analyzed by ViewIPO Financial Research Team
Healthcare ServicesIndiaFiled 2026-08-12Listed 2026-08-19Size Pending Data
Listing Price ₹118
Listing Return
₹1.99 (+1.69%)
Live Subscription
3.63x Total
Check Allotment
Status Link

Is Pramodini Medicare a Good Stock? Quick Verdict

Pramodini Medicare IPO scored 78/100 (Moderate Risk) in our deep analysis. The strongest pillar is Financial at 100/100, while Competition is the primary concern at 45/100. Pramodini Medicare Limited displays strong margin profitability and return metrics, though revenue concentration in government contracts and overall issue undersubscription warrant caution.

Stock Score
78/100
Moderate Risk

Quick Verdict

Exceptional profitability profile with an EBITDA margin of 49.61% and PAT margin of 27.91%.
Conservative capital structure indicated by a low debt-to-equity ratio of 0.34x and robust ROCE of 34.66%.
High customer concentration risk, with government (B2G) channels accounting for 61.32% of operational revenue.
Subdued public subscription interest, recording a total subscription rate of only 0.67x.

Company Snapshot

Revenue (TTM)
₹62.28Cr↑ 62.91% YoY
Profitability
PositiveNet Income ₹17.38Cr
Gross Margin
— 
Market Cap
₹65.1CrAt upper band ₹118
Issue Size
— 
Industry
Healthcare Services 
P/E Ratio
14.97xValuation Multiple
Return on Equity
32.7%Profitability
Debt to Equity
0.34xLeverage

Risk Breakdown

Governance
65
Moderate
Financial
100
Excellent
Valuation
80
Excellent
Competition
45
Expensive
Dilution
80
Excellent
Promoter / Mgmt
90
Excellent

AI Summary

Pramodini Medicare Limited is a Vijayawada-based technology-enabled diagnostic service provider operating 15 diagnostic centres across six states in India. The company delivers comprehensive services spanning radiology, clinical laboratory, and nuclear medicine through public-private partnerships, strategic PSU alliances, and private facilities. For FY26 (annualised), Pramodini Medicare reported revenue of ₹62.28 crore with an EBITDA of ₹30.90 crore and a net profit of ₹17.38 crore, showcasing strong profitability margins. The net proceeds of ₹63.14 crore from its ₹69.04 crore IPO are primarily earmarked for capital expenditure to purchase medical equipment for existing and proposed diagnostic centres.

Overall Verdict: Pramodini Medicare Limited displays strong margin profitability and return metrics, though revenue concentration in government contracts and overall issue undersubscription warrant caution.

Key Highlights

  • •Operates 15 diagnostic centres across 6 Indian states, including Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Delhi/NCR, and Kerala.
  • •Utilizes a multi-model operational framework combining public-private partnerships (PPP), private-private partnerships, strategic PSU alliances, and standalone centres.
  • •Comprehensive service portfolio spanning radiology (MRI, CT, X-ray), clinical laboratory (pathology, biochemistry), and nuclear medicine (PET-CT, SPECT).
  • •Equipped with an advanced asset base including 7 CT scans, 7 MRI machines, 15 ultrasound machines, and 1 PET-CT scanner as of December 2025.
  • •Operates a central processing unit-cum-laboratory in Vijayawada along with a 24x7 teleradiology command facility.
  • •Annualised revenue for FY26 expanded significantly to ₹62.28 crore compared to ₹38.23 crore in FY25.
  • •Issue structure comprises ₹63.14 crore fresh equity issue dedicated primarily towards purchase of diagnostic medical equipment.

Financial Performance

Revenue (Annual)

↑ +62.9% YoY

INR in Crores

Net Income (Annual)

↑ +73.1% YoY

INR in Crores

EBITDA vs PAT

↑ +47.4% YoY

INR in Crores

EBITDA
PAT

Listing Timeline

IPO Opens2026-08-12
IPO Closes2026-08-14
Basis of Allotment2026-08-17
Refunds & Demat2026-08-16
Listing Date2026-08-19

Valuation Analysis

Issue Price₹110 - ₹118
Estimated Fair Value
Pending Data
Valuation Premium
Pending
vs Fair Value

Stock DNA

Growth
72
Governance
65
Profitability
100
Valuation
80
Competition
45
Execution
90

Pros vs Cons

Pros

  • Geographically diversified footprint with 15 diagnostic centres established across six states and 13 cities.
  • High operating margins featuring an annualised EBITDA margin of 49.61% and PAT margin of 27.91%.
  • Healthy return on capital with an ROE of 32.70% and ROCE of 34.66%.
  • Low financial leverage represented by a conservative debt-to-equity ratio of 0.34x.
  • Strong technological backbone with 24x7 teleradiology capabilities and a centralized laboratory setup in Vijayawada.

Cons

  • High concentration risk with government and public entity business (B2G) driving 61.32% of total operational revenue.
  • Strict regulatory reliance on healthcare compliance, nuclear safety licenses, and state healthcare approvals.
  • Muted subscription demand across retail (0.34x) and non-institutional investor (0.16x) segments.

Financial Health

Revenue Growth
62.9% annualized expansion from FY25 to FY26 (Excellent)
Debt Level
Debt-to-Equity ratio of 0.34x (Excellent)
Cash & Equivalents
Undisclosed (Moderate)

Institutional Signals

Anchor Investors
Yes
VC Backing Tier
Undisclosed
Founder Ownership
98.75%
Strategic Partners
Tier 1 (Strategic PPPs with state government hospitals and PSUs)

Pramodini Medicare IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

Pramodini Medicare Stock — Frequently Asked Questions

Related Stock Reports

Black Opal Consultants

Black Opal Consultants

BLACK
0/100
View Report
Papadmalji Agro

Papadmalji Agro

PAPAD
0/100
View Report
EverestIMS Technologies

EverestIMS Technologies

EIMS
0/100
View Report
Pind Hospitality

Pind Hospitality

PIND
57/100
View Report
Shah Investor's Home

Shah Investor's Home

SHAHINVEST
51/100
View Report
View All Active & Upcoming Stocks & IPOs View Stock & IPO Calendar

Market Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to SaudaASBAOffer for Sale (OFS)
View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another stock or IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Pramodini Medicare

What is the expected listing price of Pramodini Medicare?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Pramodini Medicare on our Live GMP Tracker.